EGFR and lung adenocarcinoma: Furthermore, consistent with our findings, a previous study reported that ATG-10 can be used as a promising clinical predictor in advanced lung adenocarcinoma patients for gefitinib response which is an EGFR-TKI similar to Sorafenib [25].